07:47 AM EDT, 09/01/2026 (MT Newswires) -- Roche (RO.SW) signed an exclusive global licensing agreement for Simcere Zaiming's tri-specific antibody being developed as a potential treatment for B-cell-mediated diseases. Under the newly signed agreement with the Simcere Pharmaceutical Group's subsidiary, the Swiss drugmaker will gain rights to develop, manufacture, and commercialize SIM0660, according to a Tuesday release. Meanwhile, Simcere Zaiming is eligible for up to $1.53 billion in total payments, along with tiered royalties worth up to double digits on future net sales.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.